Medicare locks in permanent dialysis drug subsidies, bypassing cost controls
H.R. 6214 — Kidney Care Access Protection Act · Filed by Carol Miller (R-WV) · 18 cosponsors · Introduced Nov 20, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends and expands Medicare payment protections for new kidney dialysis drugs, devices, and education services. It guarantees that new dialysis medications approved since 2020 receive enhanced reimbursement for at least 3 years, then a permanent 65% add-on payment thereafter; extends similar protections to new dialysis equipment; requires Medicare Advantage plans to match these payments; and adds kidney disease screening and education to Medicare benefits. The primary beneficiaries are dialysis drug and device manufacturers, dialysis facilities, and patients with end-stage renal disease who gain access to newer treatments.
Why we flagged it
The bill's core mechanism is a multi-year reimbursement guarantee for new dialysis drugs and devices, structured to ensure manufacturers receive above-cost payments. While framed as expanding patient access, the primary fiscal effect is a guaranteed revenue stream for the dialysis sector.
What the text implies
- The 'permanent post-TDAPA adjustment' (Section 1) creates an indefinite entitlement to 65% of drug costs, with no sunset or budget-neutrality requirement—this is a permanent fiscal commitment that grows with new drug approvals and inflation.
- The bill explicitly exempts the adjustment from 'budget neutral manner' and 'patient-level case-mix adjustments,' meaning it bypasses standard Medicare cost-control mechanisms and will increase overall dialysis spending without offsetting reductions elsewhere.
- Medicare Advantage plans are required to match these payments (Section 102), extending the cost guarantee to private insurers and potentially raising premiums for MA enrollees.
- The 'AY modifier' requirement (Section 1) creates a new billing code that may facilitate tracking and enforcement of the add-on payments, but also signals potential future expansion of this payment model to other drug categories.
- Kidney disease screening and education expansions (Section 3) are genuine public health measures but are bundled with the payment guarantees, making it difficult to separate the public-health benefit from the industry subsidy.
Who it affects
Patients with kidney disease gain expanded access to newer treatments and preventive education, which is a genuine public health benefit. However, the bill guarantees above-market reimbursement rates (65% of costs) without budget neutrality, meaning taxpayers and other Medicare beneficiaries effectively subsidize dialysis innovation at higher cost. The permanent add-on payment creates an open-ended fiscal commitment.
Who stands to gain
- dialysis drug manufacturers
- dialysis device manufacturers
- renal dialysis facilities and chains
- Medicare Advantage insurers (pass-through cost increases)
Named in the bill
HHS Secretary, FDA, Medicare, Medicare Advantage, ESRD (End-Stage Renal Disease) prospective payment system, Section 413.234 (CFR), Section 413.236 (CFR), Section 1881 (Social Security Act), Section 1853 (Social Security Act), Humana (HUM), Origene (OGN), Elevance Health (ELV)
Where it stands
18 cosponsors: 10 Republicans, 8 Democrats.
- Nov 20, 2025 — Introduced · Congress.gov: “Introduced in House”
- Nov 20, 2025 — Referred to House Committee on Energy and Commerce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
14 lobbying clients named this bill on 18 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $5,690,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 94% of bills with at least one filing.
Carol Miller, the sponsor, reported $1,295,500 in PAC receipts in the 2026 cycle. $8,500 of that came from 1 PAC tied to these lobbying clients.
- Fresenius Medical Care North America — $2,410,000 on 2 filings
- Davita Inc — $980,000 on 1 filing
- Dialysis Patient Citizens — $750,000 on 2 filings
- Cormedix Inc. — $380,000 on 1 filing
- Akebia Therapeutics, Inc. — $360,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jun 8, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Medicare locks in permanent dialysis drug subsidies, bypassing cost controls” QuorumCivic. https://share.quorumcivic.app/bill/119/hr6214 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.